Five-year data released at the Society of Interventional Radiology meeting show that uterine artery embolization has a 73% success rate for treating uterine fibroids. Supporters hope the finding will increase the popularity of the procedure as an alternative to myomectomy or hysterectomy.
Five-year data released at the Society of Interventional Radiology meeting show that uterine artery embolization has a 73% success rate for treating uterine fibroids. Supporters hope the finding will increase the popularity of the procedure as an alternative to myomectomy or hysterectomy.
"Now that the data exist, women will be hearing more about this procedure as a minimally invasive alternative to surgery," said Dr. James B. Spies, a professor of interventional radiology at Georgetown University Hospital.
Of 200 prospective patients enrolled by Spies and colleagues in their uterine fibroid embolization trial, 182 completed the five-year follow-up after the procedure. The investigators confirmed that UAE is an effective and safe strategy to treat fibroids. They also found that UAE can control fibroid symptoms for as long or longer than does myomectomy.
The researchers followed patients at three, 12, 24, 36, 48, and 60-month intervals. They assessed patient outcomes through written questionnaires and also by keeping track of their symptom status, additional interventions, and the regularity of their menstrual cycles.
Investigators defined UAE's failure as the occurrence of a hysterectomy, a definitive myomectomy, or a repeated embolization in the preceding interval. They used summary statistics at each interval to evaluate symptom status, interval failure, and hysterectomy rates.
At five-year follow-up, researchers recorded a 73% success rate with the minimally invasive approach. Twenty-percent of patients had either failed treatment or recurred with new fibroids during the same period, including 25 hysterectomies, six myomectomies, and three repeated embolizations. At least four hysterectomies were unrelated to either recurrent fibroids or complications. Three patients died during follow-up, also of unrelated causes.
"The key question gynecologists always ask is how durable and reliable fibroid embolization is. These five-year outcomes show embolization is comparable to myomectomy but less invasive, and women recover from it more quickly," Spies said.
The long-term study results had some limitations. Researchers could not reliably assess, for instance, UAE's effects on amenorrhea. More sophisticated studies to assess all possible variables in this area are needed, Spies said.
"I'm not afraid of treating large fibroids, but now I know what to expect two or three years down the road. Now I know what to tell the patients," he said.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.